title: Curcumin prevents haloperidol-induced development of abnormal oro-facial movements: possible implications of Bcl-XL in its mechanism of action.
abstract: Curcumin (Curcuma Longa Linn), the active component of turmeric, has been shown to be effective in ameliorating several stress and drug-induced disorders in rats and humans. However, it is unclear whether short term curcumin administration can prevent the abnormal oro-facial movements (AOFM) which develop following blockade of dopamine D2 receptors by antagonist such as Haloperidol. The objective of this study is to determine whether short term treatment with curcumin along with Haloperidol can prevent the development of AOFM in rats. Male Sprague Dawley rats were administered curcumin at 200 mg/kg, and Haloperidol at 2 mg/kg daily for 2 weeks, and AOFMs and locomotor activity were assessed at baseline, day 7 and day 14. By day 14, rats receiving concurrent curcumin administration had a significant reduction in the incidence of Haloperidol-induced AOFMs, but no change on the Haloperidol-induced hypolocomotion. There was no spiked increase in locomotor activity in absence of challenge with dopamine D2 receptor agonist. The exact mechanism by which curcumin attenuates AOFMs remains unknown, therefore, we performed a proteomic analysis of the striatal samples obtained from control and curcumin treated groups. A number of proteins were altered by curcumin, among them an antiapoptotic protein, Bcl-XL, was significantly upregulated. These results suggest that curcumin may be a promising treatment to prevent the development of AOFMs and further suggest some therapeutic value in the treatment of movement disorders.
authors.affiliation: Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Christal
authors.initials: C
authors.lastname: Sookram
authors.forename: Mattea
authors.initials: M
authors.lastname: Tan
authors.forename: Ritesh
authors.initials: R
authors.lastname: Daya
authors.forename: Spencer
authors.initials: S
authors.lastname: Heffernan
authors.forename: Ram K
authors.initials: RK
authors.lastname: Mishra
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects; D003474:Curcumin / Q000494:pharmacology*; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005145:Face; D006220:Haloperidol / Q000009:adverse effects; D008297:Male; D009055:Mouth / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D051020:bcl-X Protein / Q000096:biosynthesis*
chemical_list: D014150:Antipsychotic Agents; C494813:Bcl2l1 protein, rat; D004791:Enzyme Inhibitors; D051020:bcl-X Protein; D003474:Curcumin; D006220:Haloperidol